Cite
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
MLA
Gomez, Daniel R., et al. “Local Consolidative Therapy versus Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer without Progression after First-Line Systemic Therapy: A Multicentre, Randomised, Controlled, Phase 2 Study.” The Lancet. Oncology, vol. 17, no. 12, Dec. 2016, pp. 1672–82. EBSCOhost, https://doi.org/10.1016/S1470-2045(16)30532-0.
APA
Gomez, D. R., Blumenschein, G. R., Jr, Lee, J. J., Hernandez, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tang, C., Komaki, R., Louie, A. V., Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., … Heymach, J. V. (2016). Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. The Lancet. Oncology, 17(12), 1672–1682. https://doi.org/10.1016/S1470-2045(16)30532-0
Chicago
Gomez, Daniel R, George R Blumenschein Jr, J Jack Lee, Mike Hernandez, Rong Ye, D Ross Camidge, Robert C Doebele, et al. 2016. “Local Consolidative Therapy versus Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer without Progression after First-Line Systemic Therapy: A Multicentre, Randomised, Controlled, Phase 2 Study.” The Lancet. Oncology 17 (12): 1672–82. doi:10.1016/S1470-2045(16)30532-0.